-
Mashup Score: 16Development and validation of a preliminary multivariable diagnostic model for identifying unusual infections in hospitalized patients - 18 day(s) ago
Diagnostic delay leads to poor outcomes in infections, and it occurs more often when the causative agent is unusual. Delays are attributable to failing to consider such diagnoses in a timely fashion. Using routinely collected electronic health record (EHR) data, we built a preliminary multivariable diagnostic model for early identification of unusual fungal infections and tuberculosis in hospitalized patients. We conducted a two-gate case-control study. Cases encompassed adult patients admitted to 19 Mayo Clinic enterprise hospitals between January 2010 and March 2023 diagnosed with blastomycosis, cryptococcosis, histoplasmosis, mucormycosis, pneumocystosis, or tuberculosis. Control groups were drawn from all admitted patients (random controls) and those with community-acquired infections (ID-controls). Development and validation datasets were created using randomization for dividing cases and controls (7:3), with a secondary validation using ID-controls. A logistic regression model wa
Source: www.bjbms.orgCategories: General Medicine News, Critical CareTweet
-
Mashup Score: 2CAR-macrophage versus CAR-T for solid tumors: The race between a rising star and a superstar - 4 month(s) ago
Adoptive cell therapy (ACT) has been demonstrated to be one of the most promising cancer immunotherapy strategies due to its active antitumor capabilities in vivo. Engineering T cells to overexpress chimeric antigen receptors (CARs), for example, has shown potent efficacy in the therapy of some hematologic malignancies. However, the efficacy of chimeric antigen receptor T cell (CAR-T) therapy against solid tumors is still limited due to the immunosuppressive tumor microenvironment (TME) of solid tumors, difficulty in infiltrating tumor sites, lack of tumor-specific antigens, antigen escape, and severe side effects. In contrast, macrophages expressing CARs (CAR-macrophages) have emerged as another promising candidate in immunotherapy, particularly for solid tumors. Now at its nascent stage (with only one clinical trial progressing), CAR-macrophage still shows inspiring potential advantages over CAR-T in treating solid tumors, including more abundant antitumor mechanisms and better infil
Source: www.bjbms.orgCategories: General Medicine News, Hematologists1Tweet
-
Mashup Score: 6
The Biomolecules and Biomedicine is a premier open-access biomedical journal covering a wide range of preclinical, translational and clinical research.
Source: www.bjbms.orgCategories: Latest Headlines, NeurologyTweet
Meaningful #AI for detection of unusual #infections in hospitalized patients, the first step towards game changing use of #EHR on principles of “fraud detection”; by amazing @AyssTekin https://t.co/C7BpoVnIKJ #MedTwitter @DrAndreKalil #FOAM #FOAMed @KellyCawcuttMD @PulmCrit https://t.co/s7Jkk3cYpe